Skip to main content


  • Development and validation of human relevant in vitro liver models for:
    • Hepatotoxicity screening and Drug Induced Liver Injury (DILI) prediction 
    • In vitro non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) modelling and drug target discovery 
    • Innovative culture systems towards lab-on-chip applications 
  • Novel gene therapies approaches for inherited metabolic disorders (IMD) of the liver
  • Targeting liver cell signalling in the treatment of liver disease
  • Promotion alternative methodologies through the Innovation Centre-3Rs (IC-3Rs)

  • Centralization of New Approach Methodologies (NAMs) for the Flemish and Brussels regions in one central database (RE-PLACE)

  • Advancing the next generation risk assessment (NGRA) methods
  • Developing new analytical methods for the identification of harmful ingredients towards consumer safety, in collaboration with Sciensano 
  • Flow cytometry-based high throughput screening of various hepatic cell models, for live/dead cell analysis, lipid and phospholipid accumulation
  • Microscopy-based high content analysis for lipid and mitochondrial deregulation analysis
  • Genotoxicant-specific qPCR array
  • Transcriptomics and metabolomics readouts and analysis


  • Providing regulatory and industry-orientated training in safety and efficacy of dermato-cosmetics
  • Pharmacy education of future pharmaceutical industry professionals and community pharmacists
  • Consultancy services based on expertise in in vitro experimental toxicology, stem cell technologies as well as safety and efficacy evaluation of cosmetic ingredients